Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,448.89 40.35 0.25%
S&P 500 1,868.57 3.72 0.20%
NASDAQ 4,105.74 10.22 0.25%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,512.38 -3.89 -0.03%
TOPIX 1,171.40 -1.97 -0.17%
HANG SENG 22,760.24 64.23 0.28%

Dividends, Financial Results, Presentation, Sale of Equity Stake, and Stock Purchase Agreements - Research Report on Sherwin



 Dividends, Financial Results, Presentation, Sale of Equity Stake, and Stock
   Purchase Agreements - Research Report on Sherwin-Williams, Ferro, Cytec,
                            Methanex and Chemtura

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, October 29, 2013

NEW YORK, October 29, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting The
Sherwin-Williams Company (NYSE: SHW), Ferro Corp. (NYSE: FOE), Cytec
Industries Inc. (NYSE: CYT), Methanex Corp. (NASDAQ: MEOH), and Chemtura
Corporation (NYSE: CHMT). Today's readers may access these reports free of
charge - including full price targets, industry analysis and analyst ratings -
via the links below.

The Sherwin-Williams Company Research Report

On October 16, 2013, Sherwin-Williams Company (Sherwin-Williams) announced
that its Board of Directors has  declared a regular quarterly dividend of
$0.50 per common share, payable on December 6, 2013 to holders of record as on
November 15, 2013. The Full Research Report on The Sherwin-Williams Company -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/4441_SHW]

Ferro Corp. Research Report

On October 23, 2013, Ferro Corp. (Ferro) reported its Q3 2013 financial
results. The Company reported net sales of $408.1 million, representing a
decline of 0.2% YoY. Net income attributable to common shareholders stood at
$12.7 million or $0.15 per diluted share in Q3 2013, compared to a net loss of
$316.1 million or $3.66 per share in Q3 2012. Adjusted diluted EPS stood at
$0.14 during the quarter, compared to a net loss per share of $0.02 in Q3
2012. Peter Thomas, President and CEO of Ferro, commented, "We continue to
make progress on our value creation strategy, making Ferro more competitive
and driving increased profitability. We are realizing the benefits of our cost
saving initiatives more quickly than previously anticipated and are now
expecting total savings for 2013 to be approximately $45 million. More
importantly, we estimate that our annual savings run rate at the beginning of
2014 will be approximately $70 million." The Company expects adjusted diluted
EPS for Q4 2013 to be in the range of $0.04 to $0.07 and for full-year 2013 to
be within $0.42 to $0.45. The Full Research Report on Ferro Corp. - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.analystscorner.com/r/full_research_report/e48f_FOE]

Cytec Industries Inc. Research Report

On October 18, 2013, Cytec Industries Inc. (Cytec) announced that it will
showcase its premier line of UL certified electrical insulation resins at the
Productronica 2013 in Munich, Germany, to be held from November 12 to November
15, 2013. The Company stated that electronics and electrical devices are
increasingly utilized in applications that require performance in demanding
environments such as dust, vibrations, moisture and extreme thermal cycles and
as the industry's premier supplier of UL certified electrical insulation
products, Cytec Formulated Resins has helped electronics and electrical device
makers overcome these challenges for more than 50 years. Paolo Arnaboldi,
Global Sales Director for Additive Technologies, stated, "Cytec offers one of
the industry's largest portfolios of tested and certified potting,
encapsulation and conformal coating resins in the market today. We are
committed to applying our formulated science to help our customers leverage
and optimize their businesses in the markets they serve." The Full Research
Report on Cytec Industries Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/cf91_CYT]

Methanex Corp. Research Report

On October 22, 2013, Methanex Corp. (Methanex) announced that it has agreed to
sell an approximate 10% of equity share in Egyptian Methanex Methanol Company
S.A.E. (EMethanex) to Arab Petroleum Investments Corporation (APICORP) for
$110 million. The Company informed that the transaction will increase
APICORP's ownership in EMethanex to 17%, while Methanex will continue to be
the operator and majority shareholder of EMethanex with an ownership of
slightly more that 50%. John Floren, President and CEO of Methanex commented,
"This is a win-win arrangement. The transaction aligns with APICORP's
investment strategy, and EMethanex will benefit from APICORP's growing
support. We are looking forward to continuing to build our relationship with
APICORP. In Egypt, we have built a world-class methanol facility, and we
believe our Egyptian operations will continue to create value for shareholders
today and well into the future." The Full Research Report on Methanex Corp. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/b01f_MEOH]

Chemtura Corporation Research Report

On October 10, 2013, Chemtura Corp. (Chemtura) announced that it has entered
into a stock purchase agreement to sell its Consumer Products business,
including dedicated manufacturing plants in the US and South Africa, to KIK
Custom Products Inc. for $315 million in cash. Additionally, Chemtura informed
that its board of directors has decided to explore a sale of the Company's
agrochemicals business, Chemtura AgroSolutions. Craig A. Rogerson, Chairman,
President and CEO of Chemtura said, "Following the sales of our Consumer
Products and Antioxidants businesses, a sale of Chemtura AgroSolutions would
transform Chemtura into a more focused, pure-play industrial specialty
chemicals company with leading global positions that we believe can capitalize
on attractive end-market growth trends, and continue delivering superior value
to our shareholders and opportunities for our employees for many years to
come." The Company informed that it anticipates to use a major portion of the
proceeds from the sale of Consumer Products and expected sale of the
agrochemicals business, to return capital to shareholders, to make important
investments to strengthen, and to pay down debt in order to return towards its
long-term stated total leverage target of approximately 2X Adjusted EBITDA.
The Full Research Report on Chemtura Corporation - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: [http://www.analystscorner.com/r/full_research_report/5f78_CHMT]

EDITOR NOTES:

 1. This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
 2. Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we
    are only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
 3. This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
 4. If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
 5. For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
 6. Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Namrata Maheshwari,
CFA, has only reviewed the information provided by Equity News Network in this
article or report according to the Procedures outlined by Equity News Network.
Equity News Network is not entitled to veto or interfere in the application of
such procedures by the outsourced provider to the articles, documents or
reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

www.AnalystsCorner.com

SOURCE Analysts' Corner

Contact: CONTACT PERSON: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North
America)
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement